APO Research
Talk to an analyst

APO RESEARCH · REPORT

Inactivated Influenza Virus Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Inactivated Influenza Virus Vaccine Market Analysis and Forecast 2026-2032

30 December 2025205 pages

Choose your research edition.

Industry ResearchInactivated Influenza Virus Vaccine Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Inactivated Influenza Virus Vaccine Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Inactivated Influenza Virus Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Inactivated Influenza Virus Vaccine Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Inactivated Influenza Virus Vaccine Market Analysis and Forecast 2026-2032205 pages · $4,950 USD

Market perspective

The global Inactivated Influenza Virus Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Inactivated Influenza Virus Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Inactivated Influenza Virus Vaccine include CSL, Zhejiang Tian Yuan Biopharmaceutical Co., Ltd, Changchun Institute of Biological Products Co., Ltd, Shanghai Institute of Biological Products Co., Ltd, Johnson & Johnson, Mylan, Lanzhou Institute of Biological Products Co., Ltd, Jiangsu Kangrun Biotechnology Co., Ltd and Jiangsu Jindik Biotechnology Co., Ltd, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Inactivated Influenza Virus Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Inactivated Influenza Virus Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Inactivated Influenza Virus Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Inactivated Influenza Virus Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Inactivated Influenza Virus Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Inactivated Influenza Virus Vaccine sales, projected growth trends, production technology, application and end-user industry.

Inactivated Influenza Virus Vaccine Segment by Company

CSL

Zhejiang Tian Yuan Biopharmaceutical Co., Ltd

Changchun Institute of Biological Products Co., Ltd

Shanghai Institute of Biological Products Co., Ltd

Johnson & Johnson

Mylan

Lanzhou Institute of Biological Products Co., Ltd

Jiangsu Kangrun Biotechnology Co., Ltd

Jiangsu Jindik Biotechnology Co., Ltd

Pfizer

Hualan Bio Vaccines Co., Ltd

GSK

Dalian Yalifeng Biopharmaceutical Co., Ltd

Beijing Kexing Biological Products Co., Ltd

Emmi Chengxin Biopharmaceutical Co., Ltd

AstraZeneca

Sanofi Pasteur

Inactivated Influenza Virus Vaccine Segment by Type

Whole Virus Vaccine

Subunit Vaccine

Inactivated Influenza Virus Vaccine Segment by Application

Hospital

Clinic

Inactivated Influenza Virus Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inactivated Influenza Virus Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Inactivated Influenza Virus Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inactivated Influenza Virus Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Inactivated Influenza Virus Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Inactivated Influenza Virus Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Inactivated Influenza Virus Vaccine sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Inactivated Influenza Virus Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Whole Virus Vaccine Major Manufacturers Table 3. Subunit Vaccine Major Manufacturers Table 4. Global Inactivated Influenza Virus Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Manufacturers Table 6. Clinic Major Manufacturers Table 7. Inactivated Influenza Virus Vaccine Industry Trends Table 8. Inactivated Influenza Virus Vaccine Industry Drivers Table 9. Inactivated Influenza Virus Vaccine Industry Opportunities and Challenges Table 10. Inactivated Influenza Virus Vaccine Industry Restraints Table 11. Global Inactivated Influenza Virus Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 12. Global Inactivated Influenza Virus Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 13. Global Inactivated Influenza Virus Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 14. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Region (2021-2026) Table 15. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Region (2027-2032) Table 16. Global Inactivated Influenza Virus Vaccine Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 17. Global Inactivated Influenza Virus Vaccine Sales by Region (2021-2026) & (K Units) Table 18. Global Inactivated Influenza Virus Vaccine Sales by Region (2027-2032) & (K Units) Table 19. Global Inactivated Influenza Virus Vaccine Sales Market Share by Region (2021-2026) Table 20. Global Inactivated Influenza Virus Vaccine Sales Market Share by Region (2027-2032) Table 21. Global Inactivated Influenza Virus Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 22. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 23. Global Inactivated Influenza Virus Vaccine Sales by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Inactivated Influenza Virus Vaccine Sales Market Share by Manufacturers (2021-2026) Table 25. Global Inactivated Influenza Virus Vaccine Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 26. Global Inactivated Influenza Virus Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 27. Global Inactivated Influenza Virus Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 28. Global Inactivated Influenza Virus Vaccine Manufacturers, Product Type & Application Table 29. Global Inactivated Influenza Virus Vaccine Manufacturers' Establishment Date Table 30. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 31. Global Inactivated Influenza Virus Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global Inactivated Influenza Virus Vaccine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Inactivated Influenza Virus Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 34. Global Inactivated Influenza Virus Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 35. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2021-2026) Table 36. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2027-2032) Table 37. Global Inactivated Influenza Virus Vaccine Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 38. Global Inactivated Influenza Virus Vaccine Sales by Type (2021-2026) & (K Units) Table 39. Global Inactivated Influenza Virus Vaccine Sales by Type (2027-2032) & (K Units) Table 40. Global Inactivated Influenza Virus Vaccine Sales Market Share by Type (2021-2026) Table 41. Global Inactivated Influenza Virus Vaccine Sales Market Share by Type (2027-2032) Table 42. Global Inactivated Influenza Virus Vaccine Price by Type (2021-2026) & (US$/Unit) Table 43. Global Inactivated Influenza Virus Vaccine Price by Type (2027-2032) & (US$/Unit) Table 44. Global Inactivated Influenza Virus Vaccine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Inactivated Influenza Virus Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 46. Global Inactivated Influenza Virus Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 47. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2021-2026) Table 48. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2027-2032) Table 49. Global Inactivated Influenza Virus Vaccine Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 50. Global Inactivated Influenza Virus Vaccine Sales by Application (2021-2026) & (K Units) Table 51. Global Inactivated Influenza Virus Vaccine Sales by Application (2027-2032) & (K Units) Table 52. Global Inactivated Influenza Virus Vaccine Sales Market Share by Application (2021-2026) Table 53. Global Inactivated Influenza Virus Vaccine Sales Market Share by Application (2027-2032) Table 54. Global Inactivated Influenza Virus Vaccine Price by Application (2021-2026) & (US$/Unit) Table 55. Global Inactivated Influenza Virus Vaccine Price by Application (2027-2032) & (US$/Unit) Table 56. CSL Company Information Table 57. CSL Business Overview Table 58. CSL Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 59. CSL Inactivated Influenza Virus Vaccine Product Portfolio Table 60. CSL Recent Development Table 61. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Company Information Table 62. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Business Overview Table 63. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 65. Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Recent Development Table 66. Changchun Institute of Biological Products Co., Ltd Company Information Table 67. Changchun Institute of Biological Products Co., Ltd Business Overview Table 68. Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 70. Changchun Institute of Biological Products Co., Ltd Recent Development Table 71. Shanghai Institute of Biological Products Co., Ltd Company Information Table 72. Shanghai Institute of Biological Products Co., Ltd Business Overview Table 73. Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 75. Shanghai Institute of Biological Products Co., Ltd Recent Development Table 76. Johnson & Johnson Company Information Table 77. Johnson & Johnson Business Overview Table 78. Johnson & Johnson Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Johnson & Johnson Inactivated Influenza Virus Vaccine Product Portfolio Table 80. Johnson & Johnson Recent Development Table 81. Mylan Company Information Table 82. Mylan Business Overview Table 83. Mylan Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. Mylan Inactivated Influenza Virus Vaccine Product Portfolio Table 85. Mylan Recent Development Table 86. Lanzhou Institute of Biological Products Co., Ltd Company Information Table 87. Lanzhou Institute of Biological Products Co., Ltd Business Overview Table 88. Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 90. Lanzhou Institute of Biological Products Co., Ltd Recent Development Table 91. Jiangsu Kangrun Biotechnology Co., Ltd Company Information Table 92. Jiangsu Kangrun Biotechnology Co., Ltd Business Overview Table 93. Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 95. Jiangsu Kangrun Biotechnology Co., Ltd Recent Development Table 96. Jiangsu Jindik Biotechnology Co., Ltd Company Information Table 97. Jiangsu Jindik Biotechnology Co., Ltd Business Overview Table 98. Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 100. Jiangsu Jindik Biotechnology Co., Ltd Recent Development Table 101. Pfizer Company Information Table 102. Pfizer Business Overview Table 103. Pfizer Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Pfizer Inactivated Influenza Virus Vaccine Product Portfolio Table 105. Pfizer Recent Development Table 106. Hualan Bio Vaccines Co., Ltd Company Information Table 107. Hualan Bio Vaccines Co., Ltd Business Overview Table 108. Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 110. Hualan Bio Vaccines Co., Ltd Recent Development Table 111. GSK Company Information Table 112. GSK Business Overview Table 113. GSK Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. GSK Inactivated Influenza Virus Vaccine Product Portfolio Table 115. GSK Recent Development Table 116. Dalian Yalifeng Biopharmaceutical Co., Ltd Company Information Table 117. Dalian Yalifeng Biopharmaceutical Co., Ltd Business Overview Table 118. Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 120. Dalian Yalifeng Biopharmaceutical Co., Ltd Recent Development Table 121. Beijing Kexing Biological Products Co., Ltd Company Information Table 122. Beijing Kexing Biological Products Co., Ltd Business Overview Table 123. Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 125. Beijing Kexing Biological Products Co., Ltd Recent Development Table 126. Emmi Chengxin Biopharmaceutical Co., Ltd Company Information Table 127. Emmi Chengxin Biopharmaceutical Co., Ltd Business Overview Table 128. Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio Table 130. Emmi Chengxin Biopharmaceutical Co., Ltd Recent Development Table 131. AstraZeneca Company Information Table 132. AstraZeneca Business Overview Table 133. AstraZeneca Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. AstraZeneca Inactivated Influenza Virus Vaccine Product Portfolio Table 135. AstraZeneca Recent Development Table 136. Sanofi Pasteur Company Information Table 137. Sanofi Pasteur Business Overview Table 138. Sanofi Pasteur Inactivated Influenza Virus Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Sanofi Pasteur Inactivated Influenza Virus Vaccine Product Portfolio Table 140. Sanofi Pasteur Recent Development Table 141. North America Inactivated Influenza Virus Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 142. North America Inactivated Influenza Virus Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 143. North America Inactivated Influenza Virus Vaccine Sales by Type (2021-2026) & (K Units) Table 144. North America Inactivated Influenza Virus Vaccine Sales by Type (2027-2032) & (K Units) Table 145. North America Inactivated Influenza Virus Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 146. North America Inactivated Influenza Virus Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 147. North America Inactivated Influenza Virus Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 148. North America Inactivated Influenza Virus Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 149. North America Inactivated Influenza Virus Vaccine Sales by Application (2021-2026) & (K Units) Table 150. North America Inactivated Influenza Virus Vaccine Sales by Application (2027-2032) & (K Units) Table 151. North America Inactivated Influenza Virus Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 152. North America Inactivated Influenza Virus Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 153. North America Inactivated Influenza Virus Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 154. North America Inactivated Influenza Virus Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 155. North America Inactivated Influenza Virus Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 156. North America Inactivated Influenza Virus Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 157. North America Inactivated Influenza Virus Vaccine Sales by Country (2021-2026) & (K Units) Table 158. North America Inactivated Influenza Virus Vaccine Sales by Country (2027-2032) & (K Units) Table 159. North America Inactivated Influenza Virus Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 160. North America Inactivated Influenza Virus Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 161. United States Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Table 162. Canada Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Table 163. Europe Inactivated Influenza Virus Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 164. Europe Inactivated Influenza Virus Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 165. Europe Inactivated Influenza Virus Vaccine Sales by Type (2021-2026) & (K Units) Table 166. Europe Inactivated Influenza Virus Vaccine Sales by Type (2027-2032) & (K Units) Table 167. Europe Inactivated Influenza Virus Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 168. Europe Inactivated Influenza Virus Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 169. Europe Inactivated Influenza Virus Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 170. Europe Inactivated Influenza Virus Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 171. Europe Inactivated Influenza Virus Vaccine Sales by Application (2021-2026) & (K Units) Table 172. Europe Inactivated Influenza Virus Vaccine Sales by Application (2027-2032) & (K Units) Table 173. Europe Inactivated Influenza Virus Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 174. Europe Inactivated Influenza Virus Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 175. Europe Inactivated Influenza Virus Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 176. Europe Inactivated Influenza Virus Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 177. Europe Inactivated Influenza Virus Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 178. Europe Inactivated Influenza Virus Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 179. Europe Inactivated Influenza Virus Vaccine Sales by Country (2021-2026) & (K Units) Table 180. Europe Inactivated Influenza Virus Vaccine Sales by Country (2027-2032) & (K Units) Table 181. Europe Inactivated Influenza Virus Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 182. Europe Inactivated Influenza Virus Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 183. Germany Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Table 184. France Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Table 185. U.K. Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Table 186. Italy Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Table 187. Netherlands Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Table 188. China Inactivated Influenza Virus Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 189. China Inactivated Influenza Virus Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 190. China Inactivated Influenza Virus Vaccine Sales by Type (2021-2026) & (K Units) Table 191. China Inactivated Influenza Virus Vaccine Sales by Type (2027-2032) & (K Units) Table 192. China Inactivated Influenza Virus Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 193. China Inactivated Influenza Virus Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 194. China Inactivated Influenza Virus Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 195. China Inactivated Influenza Virus Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 196. China Inactivated Influenza Virus Vaccine Sales by Application (2021-2026) & (K Units) Table 197. China Inactivated Influenza Virus Vaccine Sales by Application (2027-2032) & (K Units) Table 198. China Inactivated Influenza Virus Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 199. China Inactivated Influenza Virus Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 200. Asia Inactivated Influenza Virus Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 201. Asia Inactivated Influenza Virus Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 202. Asia Inactivated Influenza Virus Vaccine Sales by Type (2021-2026) & (K Units) Table 203. Asia Inactivated Influenza Virus Vaccine Sales by Type (2027-2032) & (K Units) Table 204. Asia Inactivated Influenza Virus Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 205. Asia Inactivated Influenza Virus Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 206. Asia Inactivated Influenza Virus Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 207. Asia Inactivated Influenza Virus Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 208. Asia Inactivated Influenza Virus Vaccine Sales by Application (2021-2026) & (K Units) Table 209. Asia Inactivated Influenza Virus Vaccine Sales by Application (2027-2032) & (K Units) Table 210. Asia Inactivated Influenza Virus Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 211. Asia Inactivated Influenza Virus Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 212. Asia Inactivated Influenza Virus Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 213. Asia Inactivated Influenza Virus Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 214. Asia Inactivated Influenza Virus Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 215. Asia Inactivated Influenza Virus Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 216. Asia Inactivated Influenza Virus Vaccine Sales by Country (2021-2026) & (K Units) Table 217. Asia Inactivated Influenza Virus Vaccine Sales by Country (2027-2032) & (K Units) Table 218. Asia Inactivated Influenza Virus Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 219. Asia Inactivated Influenza Virus Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 220. Japan Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Table 221. South Korea Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Table 222. India Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Table 223. Australia Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Table 224. China Taiwan Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Table 225. Southeast Asia Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Table 226. SAMEA Inactivated Influenza Virus Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 227. SAMEA Inactivated Influenza Virus Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 228. SAMEA Inactivated Influenza Virus Vaccine Sales by Type (2021-2026) & (K Units) Table 229. SAMEA Inactivated Influenza Virus Vaccine Sales by Type (2027-2032) & (K Units) Table 230. SAMEA Inactivated Influenza Virus Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 231. SAMEA Inactivated Influenza Virus Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 232. SAMEA Inactivated Influenza Virus Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 233. SAMEA Inactivated Influenza Virus Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 234. SAMEA Inactivated Influenza Virus Vaccine Sales by Application (2021-2026) & (K Units) Table 235. SAMEA Inactivated Influenza Virus Vaccine Sales by Application (2027-2032) & (K Units) Table 236. SAMEA Inactivated Influenza Virus Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 237. SAMEA Inactivated Influenza Virus Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 238. SAMEA Inactivated Influenza Virus Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 239. SAMEA Inactivated Influenza Virus Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 240. SAMEA Inactivated Influenza Virus Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 241. SAMEA Inactivated Influenza Virus Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 242. SAMEA Inactivated Influenza Virus Vaccine Sales by Country (2021-2026) & (K Units) Table 243. SAMEA Inactivated Influenza Virus Vaccine Sales by Country (2027-2032) & (K Units) Table 244. SAMEA Inactivated Influenza Virus Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 245. SAMEA Inactivated Influenza Virus Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 246. Brazil Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Table 247. Argentina Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Table 248. Chile Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Table 249. Colombia Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Table 250. Peru Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Table 251. Saudi Arabia Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Table 252. Israel Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Table 253. UAE Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Table 254. Turkey Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Table 255. Iran Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Table 256. Egypt Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Table 257. Key Raw Materials Table 258. Raw Materials Key Suppliers Table 259. Inactivated Influenza Virus Vaccine Distributors List Table 260. Inactivated Influenza Virus Vaccine Customers List Table 261. Research Programs/Design for This Report Table 262. Authors List of This Report Table 263. Secondary Sources Table 264. Primary Sources List of Figures Figure 1. Inactivated Influenza Virus Vaccine Image Figure 2. Global Inactivated Influenza Virus Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Inactivated Influenza Virus Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Whole Virus Vaccine Image Figure 5. Subunit Vaccine Image Figure 6. Global Inactivated Influenza Virus Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Inactivated Influenza Virus Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Global Inactivated Influenza Virus Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Inactivated Influenza Virus Vaccine Revenue (2021-2032) & (US$ Million) Figure 12. Global Inactivated Influenza Virus Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 13. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Region: 2025 Versus 2032 Figure 14. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Region (2021-2032) Figure 15. Global Inactivated Influenza Virus Vaccine Sales (2021-2032) & (K Units) Figure 16. Global Inactivated Influenza Virus Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 17. Global Inactivated Influenza Virus Vaccine Sales Market Share by Region (2021-2032) Figure 18. US & Canada & Mexico Inactivated Influenza Virus Vaccine Sales YoY (2021-2032) & (K Units) Figure 19. Europe Inactivated Influenza Virus Vaccine Sales YoY (2021-2032) & (K Units) Figure 20. China Inactivated Influenza Virus Vaccine Sales YoY (2021-2032) & (K Units) Figure 21. Asia (Excluding China) Inactivated Influenza Virus Vaccine Sales YoY (2021-2032) & (K Units) Figure 22. South America, Middle East and Africa Inactivated Influenza Virus Vaccine Sales YoY (2021-2032) & (K Units) Figure 23. Global Inactivated Influenza Virus Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 24. Global Inactivated Influenza Virus Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 25. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 26. Global Inactivated Influenza Virus Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 28. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2021-2032) Figure 29. Global Inactivated Influenza Virus Vaccine Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 30. Global Inactivated Influenza Virus Vaccine Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Inactivated Influenza Virus Vaccine Sales Market Share by Type (2021-2032) Figure 32. Global Inactivated Influenza Virus Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 34. Global Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2021-2032) Figure 35. Global Inactivated Influenza Virus Vaccine Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 36. Global Inactivated Influenza Virus Vaccine Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Inactivated Influenza Virus Vaccine Sales Market Share by Application (2021-2032) Figure 38. North America Inactivated Influenza Virus Vaccine Revenue Share by Type (2021-2032) Figure 39. North America Inactivated Influenza Virus Vaccine Sales Share by Type (2021-2032) Figure 40. North America Inactivated Influenza Virus Vaccine Revenue Share by Application (2021-2032) Figure 41. North America Inactivated Influenza Virus Vaccine Sales Share by Application (2021-2032) Figure 42. North America Inactivated Influenza Virus Vaccine Revenue Share by Country (2021-2032) Figure 43. North America Inactivated Influenza Virus Vaccine Sales Share by Country (2021-2032) Figure 44. Europe Inactivated Influenza Virus Vaccine Revenue Share by Type (2021-2032) Figure 45. Europe Inactivated Influenza Virus Vaccine Sales Share by Type (2021-2032) Figure 46. Europe Inactivated Influenza Virus Vaccine Revenue Share by Application (2021-2032) Figure 47. Europe Inactivated Influenza Virus Vaccine Sales Share by Application (2021-2032) Figure 48. Europe Inactivated Influenza Virus Vaccine Revenue Share by Country (2021-2032) Figure 49. Europe Inactivated Influenza Virus Vaccine Sales Share by Country (2021-2032) Figure 50. China Inactivated Influenza Virus Vaccine Revenue Share by Type (2021-2032) Figure 51. China Inactivated Influenza Virus Vaccine Sales Share by Type (2021-2032) Figure 52. China Inactivated Influenza Virus Vaccine Revenue Share by Application (2021-2032) Figure 53. China Inactivated Influenza Virus Vaccine Sales Share by Application (2021-2032) Figure 54. Asia Inactivated Influenza Virus Vaccine Revenue Share by Type (2021-2032) Figure 55. Asia Inactivated Influenza Virus Vaccine Sales Share by Type (2021-2032) Figure 56. Asia Inactivated Influenza Virus Vaccine Revenue Share by Application (2021-2032) Figure 57. Asia Inactivated Influenza Virus Vaccine Sales Share by Application (2021-2032) Figure 58. Asia Inactivated Influenza Virus Vaccine Revenue Share by Country (2021-2032) Figure 59. Asia Inactivated Influenza Virus Vaccine Sales Share by Country (2021-2032) Figure 60. SAMEA Inactivated Influenza Virus Vaccine Revenue Share by Type (2021-2032) Figure 61. SAMEA Inactivated Influenza Virus Vaccine Sales Share by Type (2021-2032) Figure 62. SAMEA Inactivated Influenza Virus Vaccine Revenue Share by Application (2021-2032) Figure 63. SAMEA Inactivated Influenza Virus Vaccine Sales Share by Application (2021-2032) Figure 64. SAMEA Inactivated Influenza Virus Vaccine Revenue Share by Country (2021-2032) Figure 65. SAMEA Inactivated Influenza Virus Vaccine Sales Share by Country (2021-2032) Figure 66. Inactivated Influenza Virus Vaccine Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Inactivated Influenza Virus Vaccine Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Whole Virus Vaccine
  • Subunit Vaccine
Applications
  • Hospital
  • Clinic
Companies covered
  • CSL
  • Zhejiang Tian Yuan Biopharmaceutical Co., Ltd
  • Changchun Institute of Biological Products Co., Ltd
  • Shanghai Institute of Biological Products Co., Ltd
  • Johnson & Johnson
  • Mylan
  • Lanzhou Institute of Biological Products Co., Ltd
  • Jiangsu Kangrun Biotechnology Co., Ltd
  • Jiangsu Jindik Biotechnology Co., Ltd
  • Pfizer
  • Hualan Bio Vaccines Co., Ltd
  • GSK
  • Dalian Yalifeng Biopharmaceutical Co., Ltd
  • Beijing Kexing Biological Products Co., Ltd
  • Emmi Chengxin Biopharmaceutical Co., Ltd
  • AstraZeneca
  • Sanofi Pasteur

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Inactivated Influenza Virus Vaccine Market by Type
  3. 1.2.1 Global Inactivated Influenza Virus Vaccine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Whole Virus Vaccine
  5. 1.2.3 Subunit Vaccine
  6. 1.3 Inactivated Influenza Virus Vaccine Market by Application
  7. 1.3.1 Global Inactivated Influenza Virus Vaccine Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Inactivated Influenza Virus Vaccine Market Dynamics
  1. 2.1 Inactivated Influenza Virus Vaccine Industry Trends
  2. 2.2 Inactivated Influenza Virus Vaccine Industry Drivers
  3. 2.3 Inactivated Influenza Virus Vaccine Industry Opportunities and Challenges
  4. 2.4 Inactivated Influenza Virus Vaccine Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Inactivated Influenza Virus Vaccine Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Inactivated Influenza Virus Vaccine Revenue by Region
  3. 3.2.1 Global Inactivated Influenza Virus Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Inactivated Influenza Virus Vaccine Revenue by Region (2021-2026)
  5. 3.2.3 Global Inactivated Influenza Virus Vaccine Revenue by Region (2027-2032)
  6. 3.2.4 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Inactivated Influenza Virus Vaccine Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Inactivated Influenza Virus Vaccine Sales by Region
  9. 3.4.1 Global Inactivated Influenza Virus Vaccine Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Inactivated Influenza Virus Vaccine Sales by Region (2021-2026)
  11. 3.4.3 Global Inactivated Influenza Virus Vaccine Sales by Region (2027-2032)
  12. 3.4.4 Global Inactivated Influenza Virus Vaccine Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Inactivated Influenza Virus Vaccine Revenue by Manufacturers
  2. 4.1.1 Global Inactivated Influenza Virus Vaccine Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Inactivated Influenza Virus Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Inactivated Influenza Virus Vaccine Sales by Manufacturers
  6. 4.2.1 Global Inactivated Influenza Virus Vaccine Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Inactivated Influenza Virus Vaccine Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Inactivated Influenza Virus Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Inactivated Influenza Virus Vaccine Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Inactivated Influenza Virus Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Inactivated Influenza Virus Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Inactivated Influenza Virus Vaccine Manufacturers, Product Type & Application
  13. 4.7 Global Inactivated Influenza Virus Vaccine Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Inactivated Influenza Virus Vaccine Market CR5 and HHI
  16. 4.8.2 2025 Inactivated Influenza Virus Vaccine Tier 1, Tier 2, and Tier 3
5 Inactivated Influenza Virus Vaccine Market by Type
  1. 5.1 Global Inactivated Influenza Virus Vaccine Revenue by Type
  2. 5.1.1 Global Inactivated Influenza Virus Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Inactivated Influenza Virus Vaccine Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Inactivated Influenza Virus Vaccine Sales by Type
  6. 5.2.1 Global Inactivated Influenza Virus Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Inactivated Influenza Virus Vaccine Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Inactivated Influenza Virus Vaccine Sales Market Share by Type (2021-2032)
  9. 5.3 Global Inactivated Influenza Virus Vaccine Price by Type
6 Inactivated Influenza Virus Vaccine Market by Application
  1. 6.1 Global Inactivated Influenza Virus Vaccine Revenue by Application
  2. 6.1.1 Global Inactivated Influenza Virus Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Inactivated Influenza Virus Vaccine Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Inactivated Influenza Virus Vaccine Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Inactivated Influenza Virus Vaccine Sales by Application
  6. 6.2.1 Global Inactivated Influenza Virus Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Inactivated Influenza Virus Vaccine Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Inactivated Influenza Virus Vaccine Sales Market Share by Application (2021-2032)
  9. 6.3 Global Inactivated Influenza Virus Vaccine Price by Application
7 Company Profiles
  1. 7.1 CSL
  2. 7.1.1 CSL Company Information
  3. 7.1.2 CSL Business Overview
  4. 7.1.3 CSL Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 CSL Inactivated Influenza Virus Vaccine Product Portfolio
  6. 7.1.5 CSL Recent Developments
  7. 7.2 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd
  8. 7.2.1 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Company Information
  9. 7.2.2 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Business Overview
  10. 7.2.3 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  12. 7.2.5 Zhejiang Tian Yuan Biopharmaceutical Co., Ltd Recent Developments
  13. 7.3 Changchun Institute of Biological Products Co., Ltd
  14. 7.3.1 Changchun Institute of Biological Products Co., Ltd Company Information
  15. 7.3.2 Changchun Institute of Biological Products Co., Ltd Business Overview
  16. 7.3.3 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Changchun Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  18. 7.3.5 Changchun Institute of Biological Products Co., Ltd Recent Developments
  19. 7.4 Shanghai Institute of Biological Products Co., Ltd
  20. 7.4.1 Shanghai Institute of Biological Products Co., Ltd Company Information
  21. 7.4.2 Shanghai Institute of Biological Products Co., Ltd Business Overview
  22. 7.4.3 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Shanghai Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  24. 7.4.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments
  25. 7.5 Johnson & Johnson
  26. 7.5.1 Johnson & Johnson Company Information
  27. 7.5.2 Johnson & Johnson Business Overview
  28. 7.5.3 Johnson & Johnson Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Johnson & Johnson Inactivated Influenza Virus Vaccine Product Portfolio
  30. 7.5.5 Johnson & Johnson Recent Developments
  31. 7.6 Mylan
  32. 7.6.1 Mylan Company Information
  33. 7.6.2 Mylan Business Overview
  34. 7.6.3 Mylan Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Mylan Inactivated Influenza Virus Vaccine Product Portfolio
  36. 7.6.5 Mylan Recent Developments
  37. 7.7 Lanzhou Institute of Biological Products Co., Ltd
  38. 7.7.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
  39. 7.7.2 Lanzhou Institute of Biological Products Co., Ltd Business Overview
  40. 7.7.3 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Lanzhou Institute of Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  42. 7.7.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments
  43. 7.8 Jiangsu Kangrun Biotechnology Co., Ltd
  44. 7.8.1 Jiangsu Kangrun Biotechnology Co., Ltd Company Information
  45. 7.8.2 Jiangsu Kangrun Biotechnology Co., Ltd Business Overview
  46. 7.8.3 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Jiangsu Kangrun Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  48. 7.8.5 Jiangsu Kangrun Biotechnology Co., Ltd Recent Developments
  49. 7.9 Jiangsu Jindik Biotechnology Co., Ltd
  50. 7.9.1 Jiangsu Jindik Biotechnology Co., Ltd Company Information
  51. 7.9.2 Jiangsu Jindik Biotechnology Co., Ltd Business Overview
  52. 7.9.3 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Jiangsu Jindik Biotechnology Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  54. 7.9.5 Jiangsu Jindik Biotechnology Co., Ltd Recent Developments
  55. 7.10 Pfizer
  56. 7.10.1 Pfizer Company Information
  57. 7.10.2 Pfizer Business Overview
  58. 7.10.3 Pfizer Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Pfizer Inactivated Influenza Virus Vaccine Product Portfolio
  60. 7.10.5 Pfizer Recent Developments
  61. 7.11 Hualan Bio Vaccines Co., Ltd
  62. 7.11.1 Hualan Bio Vaccines Co., Ltd Company Information
  63. 7.11.2 Hualan Bio Vaccines Co., Ltd Business Overview
  64. 7.11.3 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Hualan Bio Vaccines Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  66. 7.11.5 Hualan Bio Vaccines Co., Ltd Recent Developments
  67. 7.12 GSK
  68. 7.12.1 GSK Company Information
  69. 7.12.2 GSK Business Overview
  70. 7.12.3 GSK Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 GSK Inactivated Influenza Virus Vaccine Product Portfolio
  72. 7.12.5 GSK Recent Developments
  73. 7.13 Dalian Yalifeng Biopharmaceutical Co., Ltd
  74. 7.13.1 Dalian Yalifeng Biopharmaceutical Co., Ltd Company Information
  75. 7.13.2 Dalian Yalifeng Biopharmaceutical Co., Ltd Business Overview
  76. 7.13.3 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 Dalian Yalifeng Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  78. 7.13.5 Dalian Yalifeng Biopharmaceutical Co., Ltd Recent Developments
  79. 7.14 Beijing Kexing Biological Products Co., Ltd
  80. 7.14.1 Beijing Kexing Biological Products Co., Ltd Company Information
  81. 7.14.2 Beijing Kexing Biological Products Co., Ltd Business Overview
  82. 7.14.3 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 Beijing Kexing Biological Products Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  84. 7.14.5 Beijing Kexing Biological Products Co., Ltd Recent Developments
  85. 7.15 Emmi Chengxin Biopharmaceutical Co., Ltd
  86. 7.15.1 Emmi Chengxin Biopharmaceutical Co., Ltd Company Information
  87. 7.15.2 Emmi Chengxin Biopharmaceutical Co., Ltd Business Overview
  88. 7.15.3 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Emmi Chengxin Biopharmaceutical Co., Ltd Inactivated Influenza Virus Vaccine Product Portfolio
  90. 7.15.5 Emmi Chengxin Biopharmaceutical Co., Ltd Recent Developments
  91. 7.16 AstraZeneca
  92. 7.16.1 AstraZeneca Company Information
  93. 7.16.2 AstraZeneca Business Overview
  94. 7.16.3 AstraZeneca Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 AstraZeneca Inactivated Influenza Virus Vaccine Product Portfolio
  96. 7.16.5 AstraZeneca Recent Developments
  97. 7.17 Sanofi Pasteur
  98. 7.17.1 Sanofi Pasteur Company Information
  99. 7.17.2 Sanofi Pasteur Business Overview
  100. 7.17.3 Sanofi Pasteur Inactivated Influenza Virus Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Sanofi Pasteur Inactivated Influenza Virus Vaccine Product Portfolio
  102. 7.17.5 Sanofi Pasteur Recent Developments
8 North America
  1. 8.1 North America Inactivated Influenza Virus Vaccine Market Size by Type
  2. 8.1.1 North America Inactivated Influenza Virus Vaccine Revenue by Type (2021-2032)
  3. 8.1.2 North America Inactivated Influenza Virus Vaccine Sales by Type (2021-2032)
  4. 8.1.3 North America Inactivated Influenza Virus Vaccine Price by Type (2021-2032)
  5. 8.2 North America Inactivated Influenza Virus Vaccine Market Size by Application
  6. 8.2.1 North America Inactivated Influenza Virus Vaccine Revenue by Application (2021-2032)
  7. 8.2.2 North America Inactivated Influenza Virus Vaccine Sales by Application (2021-2032)
  8. 8.2.3 North America Inactivated Influenza Virus Vaccine Price by Application (2021-2032)
  9. 8.3 North America Inactivated Influenza Virus Vaccine Market Size by Country
  10. 8.3.1 North America Inactivated Influenza Virus Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Inactivated Influenza Virus Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Inactivated Influenza Virus Vaccine Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Inactivated Influenza Virus Vaccine Market Size by Type
  2. 9.1.1 Europe Inactivated Influenza Virus Vaccine Revenue by Type (2021-2032)
  3. 9.1.2 Europe Inactivated Influenza Virus Vaccine Sales by Type (2021-2032)
  4. 9.1.3 Europe Inactivated Influenza Virus Vaccine Price by Type (2021-2032)
  5. 9.2 Europe Inactivated Influenza Virus Vaccine Market Size by Application
  6. 9.2.1 Europe Inactivated Influenza Virus Vaccine Revenue by Application (2021-2032)
  7. 9.2.2 Europe Inactivated Influenza Virus Vaccine Sales by Application (2021-2032)
  8. 9.2.3 Europe Inactivated Influenza Virus Vaccine Price by Application (2021-2032)
  9. 9.3 Europe Inactivated Influenza Virus Vaccine Market Size by Country
  10. 9.3.1 Europe Inactivated Influenza Virus Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Inactivated Influenza Virus Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Inactivated Influenza Virus Vaccine Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Inactivated Influenza Virus Vaccine Market Size by Type
  2. 10.1.1 China Inactivated Influenza Virus Vaccine Revenue by Type (2021-2032)
  3. 10.1.2 China Inactivated Influenza Virus Vaccine Sales by Type (2021-2032)
  4. 10.1.3 China Inactivated Influenza Virus Vaccine Price by Type (2021-2032)
  5. 10.2 China Inactivated Influenza Virus Vaccine Market Size by Application
  6. 10.2.1 China Inactivated Influenza Virus Vaccine Revenue by Application (2021-2032)
  7. 10.2.2 China Inactivated Influenza Virus Vaccine Sales by Application (2021-2032)
  8. 10.2.3 China Inactivated Influenza Virus Vaccine Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Inactivated Influenza Virus Vaccine Market Size by Type
  2. 11.1.1 Asia Inactivated Influenza Virus Vaccine Revenue by Type (2021-2032)
  3. 11.1.2 Asia Inactivated Influenza Virus Vaccine Sales by Type (2021-2032)
  4. 11.1.3 Asia Inactivated Influenza Virus Vaccine Price by Type (2021-2032)
  5. 11.2 Asia Inactivated Influenza Virus Vaccine Market Size by Application
  6. 11.2.1 Asia Inactivated Influenza Virus Vaccine Revenue by Application (2021-2032)
  7. 11.2.2 Asia Inactivated Influenza Virus Vaccine Sales by Application (2021-2032)
  8. 11.2.3 Asia Inactivated Influenza Virus Vaccine Price by Application (2021-2032)
  9. 11.3 Asia Inactivated Influenza Virus Vaccine Market Size by Country
  10. 11.3.1 Asia Inactivated Influenza Virus Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Inactivated Influenza Virus Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Inactivated Influenza Virus Vaccine Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Inactivated Influenza Virus Vaccine Market Size by Type
  2. 12.1.1 SAMEA Inactivated Influenza Virus Vaccine Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Inactivated Influenza Virus Vaccine Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Inactivated Influenza Virus Vaccine Price by Type (2021-2032)
  5. 12.2 SAMEA Inactivated Influenza Virus Vaccine Market Size by Application
  6. 12.2.1 SAMEA Inactivated Influenza Virus Vaccine Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Inactivated Influenza Virus Vaccine Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Inactivated Influenza Virus Vaccine Price by Application (2021-2032)
  9. 12.3 SAMEA Inactivated Influenza Virus Vaccine Market Size by Country
  10. 12.3.1 SAMEA Inactivated Influenza Virus Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Inactivated Influenza Virus Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Inactivated Influenza Virus Vaccine Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Inactivated Influenza Virus Vaccine Value Chain Analysis
  2. 13.1.1 Inactivated Influenza Virus Vaccine Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Inactivated Influenza Virus Vaccine Production Mode & Process
  6. 13.2 Inactivated Influenza Virus Vaccine Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Inactivated Influenza Virus Vaccine Distributors
  9. 13.2.3 Inactivated Influenza Virus Vaccine Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst